Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer analgesic

Executive Summary

Natl. Institute on Drug Abuse Director Charles Schuster told a meeting of the Natl. Advisory Council on Drug Abuse Sept. 16 that an NIAD grantee, Tony Yaksh, Mayo Clinic, "has shown that an opioid peptide, D-Ala2-DO-Leu5-enkephalin (DADL), binds to the brain's delta opiate receptor to produce analgesia in cancer patients." Schuster said the discovery is "an important step toward the development of a non-addictive pain-killer that could replace morphine".

Latest Headlines
See All
UsernamePublicRestriction

Register

PS010780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel